Skip to search formSkip to main contentSkip to account menu

60 ACTUAT olodaterol 0.0025 MG/ACTUAT / tiotropium 0.0025 MG/ACTUAT Metered Dose Inhaler

Known as: tiotropium bromide 2.5 MCG / olodaterol 2.5 MCG per INHAL Metered Dose Inhaler, 60 ACTUAT, OLODATEROL 2.5MCG/TIOTROPIUM 2.5MCG/ACTUAT INHL,ORAL,60D,4GM [VA Product], OLODATEROL/TIOTROP 2.5MCG/ACTUAT 60D INH 
National Institutes of Health

Related topics

Related topics

5 relations
AsthmaMetered Dose Inhalerolodaterololodaterol / tiotropium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Improving the Efficiency of Randomized Trials: The DYNAGITO Example
Abstract A traditional principle of the randomized controlled trial is that the p-value comparing treatment groups should be… 
2019
2019
S137 Short-acting and long-acting β2-agonists upregulate asthma-relevant pro-inflammatory mediators in human airway epithelial cells while short-acting muscarinic antagonists do not
Introduction and objectives Despite their undoubted benefits, increased mortality is associated with overuse of short-acting β2… 
2016
2016
P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold b
R Buhl reports financial support to his institution from Boehringer Ingelheim during the conduct of the study and, outside of the… 
2016
2016
Tiotropium + Olodaterol Fixed-Dose Combination Therapy Provides Lung-Function Benefits Compared With Tiotropium Alone In Patients With GOLD A/B And C/D Chronic Obstructive Pulmonary Disease: Post Hoc…
2016
2016
Tiotropium Bromide/Olodaterol as Maintenance Treatment for Patients with COPD
Chronic obstructive pulmonary disease (COPD) requires appropriate treatment regimens, since it is a major cause of morbidity and… 
2015
2015
Effect of Tiotropium + Olodaterol on the Use of Nighttime Rescue Medication in Patients With COPD: Results From Four Randomized, Double-Blind Studies
2015
2015
長時間作用性β2刺激薬・オロダテロールのCOPD に対する臨床的有用性
Olodaterol, a once︱daily, long︱acting beta2︱agonist（LABA）, has recently been regulatory approved overseas with indication of… 
2013
2013
P230 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies
Background The novel LABA olodaterol has 24-h bronchodilator activity. Objective To evaluate the symptomatic benefit of… 
2013
2013
48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis
Background: The novel LABA olodaterol (O) has an acceptable safety profile in clinical studies of ≤4 weeks (wks). Objective: To… 
2013
2013
Struktur und Funktion β-adrenerger Rezeptoren Structure and function of β-adrenergic receptors
fische Verteilung der Rezeptorsubtypen vorzuliegen, sondern vielmehr eine unterschiedliche Dichte der Rezeptorsubtypen in den… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)